Among the most prominent forms of immunotherapy are immune checkpoint inhibitors (ICIs), which block proteins (such as PD-1, PD-L1, and CTLA-4) that cancer cells or immune cells use to weaken the immune response, allowing a more robust attack on tumors. This evidence concerns the gene CTLA4 and cancer.